Tirzepatide India: Lilly and Cipla Expand Access to Advanced Diabetes and Obesity Care India may soon see wider access to Tirzepatide, one of the most potent therapies approved for use in people with type 2 diabetes and chronic weight management, as Eli Lilly and Company India recently signed an agreement with Cipla Limited, allowing the pharmaceutical company Cipla to distribute and promote the drug under a second brand name Yurpeak throughout India
The tumor suppressor PTEN inhibits the integrin-mediated outside-in signals[148], while targeted silencing of FAK through specific small interfering RNA (siRNA) further diminishes fibrosis, decreases collagen content, suppresses MMP-2 activity, and reverses cardiac hypertrophy and failure induced by mechanical stress overload[150]
Osuka S, Nakanishi N, Murase T, et al
A possible role for mitochondrial dysfunction in migraine
A review of 26 studies showed that GLP-1s can improve things like blood sugar control and period regularity in people with PCOS
A provider may prescribe a compounded version of a medication so the patient can save money, when they have trouble finding Rybelsus, Ozempic, or Wegovy in stock, or due to allergies